Product NDC: | 21695-139 |
Proprietary Name: | Butalbital, Aspirin, and Caffeine |
Non Proprietary Name: | butalbital, aspirin, and caffeine |
Active Ingredient(s): | 325; 50; 40 mg/1; mg/1; mg/1 & nbsp; butalbital, aspirin, and caffeine |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 21695-139 |
Labeler Name: | Rebel Distributors Corp |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA086231 |
Marketing Category: | ANDA |
Start Marketing Date: | 20030918 |
Package NDC: | 21695-139-60 |
Package Description: | 60 CAPSULE in 1 BOTTLE (21695-139-60) |
NDC Code | 21695-139-60 |
Proprietary Name | Butalbital, Aspirin, and Caffeine |
Package Description | 60 CAPSULE in 1 BOTTLE (21695-139-60) |
Product NDC | 21695-139 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | butalbital, aspirin, and caffeine |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 20030918 |
Marketing Category Name | ANDA |
Labeler Name | Rebel Distributors Corp |
Substance Name | ASPIRIN; BUTALBITAL; CAFFEINE |
Strength Number | 325; 50; 40 |
Strength Unit | mg/1; mg/1; mg/1 |
Pharmaceutical Classes | Barbiturate [EPC],Barbiturates [Chemical/Ingredient],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Central Nervous System Stimulant [EPC],Central Nervous System Stimulation [PE],Methylxanthine [EPC],Xanthines [Chemical/Ingredient] |